Cardiovascular Toxicology is a pivotal journal dedicated to advancing the understanding of the interplay between toxic substances and cardiovascular health. Published by HUMANA PRESS INC, this journal serves as a critical resource for researchers and professionals in the fields of cardiology, toxicology, and molecular biology. With an ISSN of 1530-7905 and an E-ISSN of 1559-0259, it has established itself as a key source of high-quality research since its inception in 2001, continuing to contribute valuable insights through 2024. The journal enjoys a robust reputation, evidenced by its Q2 ranking in both Cardiology and Cardiovascular Medicine and Toxicology, along with a Q3 ranking in Molecular Biology for 2023. With Scopus rankings placing it in the 80th percentile for Cardiology and 71st for Toxicology, Cardiovascular Toxicology attracts submissions that reflect cutting-edge research and innovative methodologies. Notably, the journal prioritizes stringent peer review and scholarly rigor, ensuring that published works significantly impact the understanding of cardiovascular responses to various toxic agents. Though not an open-access journal, its content remains highly sought after in a diverse scholarly community, making it indispensable for those dedicated to enhancing cardiovascular disease prevention, diagnosis, and treatment through toxicological insights.

Environmental Epigenetics, published by Oxford University Press, is a leading open access journal dedicated to advancing the understanding of the epigenetic mechanisms that underpin environmental influences on health and disease. With an ISSN of 2058-5888 and established as an open access platform since 2015, this journal serves as a vital resource for researchers in the fields of genetics, environmental science, and health, offering insights from multidisciplinary perspectives. The journal has gained notable recognition in the academic community, reflected by its impressive Scopus rankings and its classification in the second quartile (Q2) for Genetics and other related disciplines as of 2023. It aims to foster innovative research that bridges laboratory findings and real-world environmental issues, making it an indispensable tool for professionals and students pursuing knowledge at the intersection of genetics, environmental science, and public health. With its commitment to disseminating valuable research findings freely, Environmental Epigenetics stands out as an essential publication for those aiming to understand the significant impacts of environmental factors on genetic expression.

Chemical Research in Toxicology is a premier journal published by the American Chemical Society, dedicated to advancing the understanding of toxicological effects associated with chemical substances. Since its inception in 1988, this esteemed journal has maintained a robust impact factor, ranking in the Q1 quartile for both Medicine (miscellaneous) and Toxicology as of 2023, reflecting its significance and influence in the fields of pharmacology and toxicology. With an impressive Scopus ranking at #16 out of 133 in the Toxicology category, it serves as a vital resource for researchers, professionals, and students seeking cutting-edge insights and scholarly articles that bridge the gap between chemistry and toxicological science. Although not an open-access publication, it continues to provide comprehensive analyses and original research that inform safe chemical practices and regulatory policies, further enhancing its role in public health and safety.

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, published by Elsevier, stands as a premier journal in the fields of Genetics and Health, Toxicology and Mutagenesis, boasting a Q1 ranking in both categories for 2023. With an impressive impact factor and rigorous peer-review process, this journal serves as a vital platform for disseminating cutting-edge research and comprehensive reviews regarding the implications of genetic mutations and related health effects. Established in the Netherlands, it has evolved from its inception in the early 1990s to become an essential resource for researchers, professionals, and students alike, facilitating advancements in the understanding of mutation research. Despite not offering an open-access model, the journal ensures a wide reach through institutional subscriptions, emphasizing its commitment to fostering scholarly dialogue and promoting significant findings within the scientific community.

Clinical Epigenetics is a pioneering open-access journal published by BMC, dedicated to advancing the field of epigenetics and its critical implications in clinical and translational research. Established in 2011, the journal has become an authoritative resource in the realms of developmental biology, genetics, and molecular biology, as evidenced by its impressive 2023 Scopus categorization as a Q1 journal in multiple domains including clinical genetics. With a robust impact factor and rankings that place it among the top quartiles in its fields—Rank #13 in Clinical Genetics and #14 in Developmental Biology—Clinical Epigenetics serves as an essential platform for researchers, professionals, and students alike, encouraging the dissemination of high-quality research findings. Operating from its United Kingdom headquarters, this journal not only contributes to scholarly dialogue across the globe but also supports unrestricted access to vital findings that push the boundaries of our understanding of epigenetic mechanisms and their clinical applications.

Reports of Biochemistry and Molecular Biology, published by VARASTEGAN INST MEDICAL SCIENCES, is a distinguished open access journal dedicated to advancing the fields of biochemistry and molecular biology. Since its inception in 2012, the journal has fostered a platform for researchers and professionals to disseminate their findings, contributing to a richer understanding of biochemical processes and molecular mechanisms. With a focus on innovative research and technology, the journal has established itself as a significant resource within its field, being classified in the Q3 category for Biochemistry and Molecular Biology by 2023. Notably, it has achieved respectable Scopus rankings, including a rank of #40/72 in Biochemistry (medical) as well as a common ground across multiple related categories. The journal’s commitment to open access ensures that its valuable content is freely available to the global scientific community, facilitating knowledge sharing among students, researchers, and professionals alike. Located in Mashhad, Iran, Reports of Biochemistry and Molecular Biology serves as a bridge between cutting-edge research and practical applications in the biochemistry and molecular biology domains.

JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES, published by Taylor & Francis Inc, stands as a key resource in the interdisciplinary field of toxicology and environmental health. Operating under the ISSN 1528-7394 and E-ISSN 1087-2620, this journal maintains a strong presence with a Q2 category ranking in Health, Toxicology and Mutagenesis and a Q3 ranking in Toxicology as of 2023. It aims to disseminate critical findings that address contemporary issues in toxicology and environmental health, emphasizing the implications of environmental agents on human health. The journal offers both subscription and open access options, making cutting-edge research accessible to a diverse readership. With coverage of key topics from 1998 to 2024, it is an essential platform for academics, professionals, and students seeking to stay at the forefront of environmental health sciences.